Loïc Verlingue

3.4k total citations · 1 hit paper
51 papers, 1.4k citations indexed

About

Loïc Verlingue is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Loïc Verlingue has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 17 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Loïc Verlingue's work include Cancer Genomics and Diagnostics (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Treatments and Mutations (8 papers). Loïc Verlingue is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Treatments and Mutations (8 papers). Loïc Verlingue collaborates with scholars based in France, United Kingdom and Spain. Loïc Verlingue's co-authors include Antoine Hollebecque, Aurélien Marabelle, Christophe Massard, Charles Ferté, Stéphane Champiat, Jean‐Yves Scoazec, David Brandão, Jean‐Charles Soria, Samy Ammari and Roger Sun and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Loïc Verlingue

43 papers receiving 1.4k citations

Hit Papers

A radiomics approach to assess tumour-infiltrating CD8 ce... 2018 2026 2020 2023 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
    2018 825 citations Roger Sun, Elaine Johanna Limkin et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Loïc Verlingue France 14 719 640 463 276 242 51 1.4k
Jean‐Philippe Metges France 22 1.2k 1.6× 719 1.1× 817 1.8× 709 2.6× 252 1.0× 113 2.2k
Andrea Lancia Italy 17 532 0.7× 834 1.3× 792 1.7× 165 0.6× 156 0.6× 59 1.6k
Wen-Fei Li China 23 920 1.3× 405 0.6× 592 1.3× 662 2.4× 199 0.8× 63 1.9k
Adrianus J. de Langen Netherlands 24 1.1k 1.5× 1.0k 1.6× 1.5k 3.2× 174 0.6× 270 1.1× 49 2.5k
Joshua Chaim United States 14 458 0.6× 311 0.5× 732 1.6× 255 0.9× 287 1.2× 39 1.3k
David Brandão France 3 476 0.7× 609 1.0× 329 0.7× 107 0.4× 120 0.5× 4 934
Raquibul Hannan United States 28 637 0.9× 460 0.7× 1.3k 2.7× 356 1.3× 366 1.5× 110 2.1k
Young Wha Koh South Korea 26 892 1.2× 284 0.4× 563 1.2× 197 0.7× 242 1.0× 82 1.7k
Laëtitia Vercellino France 25 788 1.1× 1.1k 1.8× 517 1.1× 196 0.7× 572 2.4× 81 2.2k
Ferry Lalezari Netherlands 15 1.0k 1.4× 434 0.7× 1.0k 2.2× 170 0.6× 120 0.5× 33 1.7k

Countries citing papers authored by Loïc Verlingue

Since Specialization
Citations

This map shows the geographic impact of Loïc Verlingue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loïc Verlingue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loïc Verlingue more than expected).

Fields of papers citing papers by Loïc Verlingue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loïc Verlingue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loïc Verlingue. The network helps show where Loïc Verlingue may publish in the future.

Co-authorship network of co-authors of Loïc Verlingue

This figure shows the co-authorship network connecting the top 25 collaborators of Loïc Verlingue. A scholar is included among the top collaborators of Loïc Verlingue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loïc Verlingue. Loïc Verlingue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Texier, Vincent Le, et al.. (2025). A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board. npj Precision Oncology. 9(1). 28–28.
2.
3.
Corbaux, Pauline, Armelle Vinceneux, Hélène Vanacker, et al.. (2024). Patients’ selection and trial matching in early-phase oncology clinical trials. Critical Reviews in Oncology/Hematology. 196. 104307–104307. 5 indexed citations
4.
Reig, Òscar, Laurence Crouzet, Andrea Necchi, et al.. (2024). 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1. Annals of Oncology. 35. S515–S516. 3 indexed citations
5.
McKean, Meredith, Òscar Reig, Elisa Fontana, et al.. (2024). 654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors. Annals of Oncology. 35. S517–S517. 1 indexed citations
6.
Verlingue, Loïc, et al.. (2024). Artificial intelligence in oncology: ensuring safe and effective integration of language models in clinical practice. The Lancet Regional Health - Europe. 46. 101064–101064. 16 indexed citations
7.
8.
Verlingue, Loïc, Qing Wang, Olivier Trédan, et al.. (2024). The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST. Acta Oncologica. 63. 411–417.
9.
Baldini, Capucine, Tarek Assi, Alice Bernard‐Tessier, et al.. (2022). Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer. 167. 42–53. 3 indexed citations
10.
Martín-Romano, Patricia, Léo Colmet‐Daage, Daphné Morel, et al.. (2022). Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. European Journal of Cancer. 173. 133–145. 1 indexed citations
11.
Morel, Daphné, François‐Xavier Danlos, Aurélien Marabelle, et al.. (2021). Applications of single-cell and bulk RNA sequencing in onco-immunology. European Journal of Cancer. 149. 193–210. 81 indexed citations
12.
Soria, Jean‐Charles, et al.. (2021). Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. JCO Clinical Cancer Informatics. 5(5). 709–718. 11 indexed citations
13.
Facchinetti, Fabio, Ratislav Bahleda, Loïc Verlingue, et al.. (2021). 34MO Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials. Annals of Oncology. 32. S14–S15. 1 indexed citations
14.
Hollebecque, Antoine, Lambros Tselikas, Michel Ducreux, et al.. (2020). 70P Genomic landscape and efficacy of precision medicine in biliary tract cancers. Annals of Oncology. 31. S267–S268. 2 indexed citations
15.
Verlingue, Loïc, Antoine Hollebecque, Ludovic Lacroix, et al.. (2018). Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Annals of Oncology. 29. viii667–viii667. 1 indexed citations
16.
Verlingue, Loïc, Sophie Broutin, Mehdi Touat, et al.. (2018). Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas. European Journal of Cancer. 90. 83–91. 29 indexed citations
17.
Sun, Roger, Elaine Johanna Limkin, Maria Vakalopoulou, et al.. (2018). A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. The Lancet Oncology. 19(9). 1180–1191. 825 indexed citations breakdown →
18.
19.
Verlingue, Loïc, Nathalie Cozic, Matthieu Faron, et al.. (2017). Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Seminars in Oncology. 44(2). 114–128. 14 indexed citations
20.
Bonnet, Clément, Guillaume Beinse, Luc Cabel, et al.. (2016). ESMO ECCO 2015 : les temps forts de l’immunothérapie et des thérapies ciblées. Bulletin du Cancer. 103(6). 594–603. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Philippe Metges Breakdown of academic impact, for papers by Andrea Lancia Breakdown of academic impact, for papers by Wen-Fei Li Breakdown of academic impact, for papers by Adrianus J. de Langen Breakdown of academic impact, for papers by Joshua Chaim Breakdown of academic impact, for papers by David Brandão Breakdown of academic impact, for papers by Raquibul Hannan Breakdown of academic impact, for papers by Young Wha Koh Breakdown of academic impact, for papers by Laëtitia Vercellino Breakdown of academic impact, for papers by Ferry Lalezari
Rankless by CCL
2026